Therapy Shows Early, Encouraging Results in Treating Aggressive Form of Breast Cancer

Article

Merck's anti"PD-1 therapy Keytruda has demonstrated an overall response rate of 18.5% among patients with PD-L1 positive, advanced triple-negative breast cancer, one of the most aggressive forms of breast cancer.

Merck’s anti—PD-1 therapy Keytruda has demonstrated an overall response rate of 18.5% among patients with PD-L1 positive, advanced triple-negative breast cancer, one of the most aggressive forms of breast cancer.

With more data to be collected from responders, Merck celebrated favorable, early results in a press release.

“Metastatic, triple-negative breast cancer is an aggressive and often difficult-to-treat disease,” said Rita Nanda, MD, associate director of breast medical oncology at the University of Chicago and principal investigator for the Keytruda triple-negative breast cancer phase 1b study cohort, in a press release. “The results presented at this year’s SABCS, while early, show encouraging anti-tumor activity in these patients, most of whom had received multiple prior chemotherapies.”

Many patients in the study had received 2 or more prior chemotherapies for metastatic disease, Merck stated, and 87.5% had received prior neo-adjuvant or adjuvant therapy.

Of the 27 patients studied, 3.7% achieved a complete response and 14.8% saw a partial response. On the flip side, 25.9% saw stable disease, 44.4% deteriorated with progressive disease, and 11.1% discontinued therapy.

Merck also noted that 33% of patients taking Keytruda experienced tumor shrinkage.

Some of Keytruda’s reported adverse side effects included arthralgia, fatigue, myalgia, and nausea, according to Merck.

Related Videos
Health care provider examining MRI images of patient with multiple sclerosis -- Image credit: New Africa | stock.adobe.com
Opill manufacturing | Perrigo
Healthy food selection - Image credit: Alexander Raths | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.